Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma

American Journal of Hematology

Volumn 85, Issue 1, 2010, Pages 87-90

  Corazzelli, Gaetano ^a   De Filippi, Rosaria ^a,b   Capobianco, Gaetana ^a   Frigeri, Ferdinando ^a   De Rosa, Vincenzo ^c   Iaccarino, Giancarla ^a   Russo, Filippo ^a   Arcamone, Manuela ^a   Becchimanzi, Cristina ^a   Crisci, Stefania ^a   Marcacci, Gianpaolo ^a   Amoroso, Barbara ^d   Lastoria, Secondo ^c   Pinto, Antonio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d Binding Site Group Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; LENALIDOMIDE; METHYLPREDNISOLONE; NAPROXEN; TRAMADOL; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; THALIDOMIDE;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; B LYMPHOCYTE; CANCER GRADING; CANCER SURVIVAL; CASE REPORT; CLASSICAL HODGKIN LYMPHOMA; DIARRHEA; FATIGUE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; PALLIATIVE THERAPY; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; STEROID THERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR FLARE; TUMOR GROWTH; CHEMICALLY INDUCED DISORDER; COMPASSIONATE USE; HODGKIN DISEASE; IMMUNOLOGY; INFLAMMATION; LETTER; PATHOLOGY; TUMOR RECURRENCE;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; COMPASSIONATE USE TRIALS; HODGKIN DISEASE; HUMANS; INFLAMMATION; MALE; NEOPLASM RECURRENCE, LOCAL; THALIDOMIDE; YOUNG ADULT;

EID: 74049139971     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21571     Document Type: Article

References (15)

1. Brice P. Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol 2008;141:3-13.
2. Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008;26:1544-1552.
3. Kuppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009;9:15-27.
4. Verhelle D, Corral LG, Wong K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007;67:746-755.
5. Cheson BD, P.stner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586.
6. Tecchio C, Nadali G, Scapini P, et al. High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma. Br J Haematol 2007;137:553-559.
7. Pratt G. The evolving use of serum free light chain assays in haematology. Br J Haematol 2008;141:413-422.
8. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291-5297.
9. Andritsos LA, Johnson AJ, Lozanski G, et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor .are in patients with chronic lymphocytic leukemia. J Clin Oncol 2008;26:2519-2525.
10. Chanan-Khan A, Miller KC, Musial L, et al. Clinical ef.cacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006;24:5343-5349.
11. Chanan-Khan AA, Whitworth A, Bangia N, et al. Lenalidomide-associated tumor .are reaction is manageable in patients with chronic lymphocytic leukemia. J Clin Oncol 2008;26:4851-4852.
12. Borchmann P, Topp M, Reiners K, et al. Early report on the activity of lenalidomide in chemotherapy-refractory Hodgkin lymphoma patients. Ann Oncol 2008;19 (Suppl. 4):iv167.
13. Fehniger TA, Larson S, Trinkaus K, et al. A phase II multicenter study of lenalidomide in patients with relapsed or refractory classical Hodgkin lymphoma (cHL): Preliminary results. Blood 2008;112:2595 (ASH Annual Meeting Abstracts).
14. Kuruvilla J, Taylor D, Wang L, et al. Phase II trial of lenalidomide in patients with relapsed or refractory Hodgkin Lymphoma. Blood 2008;112:3052 (ASH Annual Meeting Abstracts).
15. Thio M, Blokhuis BR, Nijkamp FP, Redegeld FA. Free immunoglobulin light chains: A novel target in the therapy of in.ammatory diseases. Trends Pharmacol Sci 2008;29:170-174.